Our Pricing

The Science Behind Mounjaro On NHS

Understanding mounjaro on nhs how does it work requires looking at its unique dual-hormone mechanism and current UK prescribing pathways. At Cured Pharmacy, our UK-registered clinical team explains the science behind tirzepatide and how you can access this treatment through private prescription from £135.00, subject to clinical assessment by a UK prescriber.

How Mounjaro Works: The Dual GIP/GLP-1 Mechanism

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA in the UK [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates two complementary hormone pathways that naturally regulate appetite, blood glucose, and energy metabolism.

The GLP-1 component slows gastric emptying and reduces appetite by acting on brain receptors that control hunger signals, whilst the GIP receptor activation enhances insulin secretion and may improve fat metabolism [1]. This dual action produces significantly greater weight reduction compared to GLP-1-only treatments in head-to-head clinical trials.

In the landmark SURPASS-3 trial involving 1,444 participants with type 2 diabetes, patients receiving the 15mg Mounjaro dose achieved an average body weight reduction of 22.5% over 72 weeks — substantially higher than the 15% average seen with semaglutide 1mg in comparable studies [1][2]. These results led to MHRA approval for both diabetes management and chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities.

Mounjaro on NHS: Current Eligibility and Prescribing Guidelines

NICE guidance published in March 2024 recommends tirzepatide as a treatment option for chronic weight management in adults through specialist NHS weight management services [3]. However, NHS availability remains extremely limited due to capacity constraints within specialist services and regional commissioning variations across England, Scotland, Wales, and Northern Ireland.

To qualify for NHS prescription where available, patients typically must meet strict criteria including a BMI of 35 kg/m² or above (or 32.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds), have attempted structured weight loss programmes without success, and be referred through a specialist tier 3 or tier 4 weight management service [3].

Most UK patients currently access Mounjaro through private prescription due to NHS waiting lists that can extend 12-18 months in many areas. At Cured Pharmacy, our UK-registered prescribers conduct comprehensive clinical assessments to determine suitability, with treatment available from £135.00 for eligible patients following online consultation.

Private Prescription vs NHS Pathways

Private prescription offers immediate access following clinical assessment, with no waiting lists or referral requirements. Your Cured Pharmacy prescriber evaluates your medical history, current medications, weight loss goals, and any contraindications during a free online consultation typically completed in under three minutes. If approved, your medication is dispensed from our UK-registered pharmacy with discreet next-day delivery available across England, Scotland, Wales, and Northern Ireland.

Clinical Evidence: What the SURPASS Trials Show

The SURPASS clinical trial programme represents the most comprehensive evaluation of tirzepatide's efficacy and safety across diverse patient populations. SURPASS-1 through SURPASS-5 enrolled over 6,000 participants with type 2 diabetes, whilst the SURMOUNT trials specifically examined weight management in adults without diabetes [1][4].

SURMOUNT-1, published in the New England Journal of Medicine, demonstrated that adults without diabetes receiving 15mg tirzepatide weekly achieved an average weight reduction of 20.9% from baseline over 72 weeks, compared to 3.1% with placebo [4]. Importantly, 91% of participants on the highest dose achieved at least 5% weight loss — the threshold associated with meaningful health improvements — and 57% achieved at least 20% weight loss.

Safety data from these trials showed the most common side effects were gastrointestinal, including nausea (reported by 29-43% of participants), diarrhoea (21-27%), and vomiting (9-14%), typically mild to moderate and decreasing over time [1][4]. Serious adverse events were rare, occurring in fewer than 7% of participants across treatment groups.

Long-Term Metabolic Benefits

Beyond weight reduction, clinical trials demonstrated improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers [1]. Participants experienced average reductions in HbA1c of 2.0-2.3% when starting from baseline levels above 8%, alongside improvements in liver enzyme markers suggesting reduced hepatic fat accumulation. These metabolic benefits occurred alongside weight loss and were sustained throughout the 72-week study periods, though long-term data beyond two years remains limited.

Mounjaro Dosing: The Gradual Escalation Protocol

Mounjaro treatment follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising therapeutic benefit. All patients begin with a 2.5mg once-weekly subcutaneous injection for the first four weeks, regardless of their target maintenance dose [5].

After the initial four-week period, your prescriber will typically increase the dose to 5mg weekly, with further increases to 7.5mg, 10mg, 12.5mg, or 15mg at four-week intervals based on your response and tolerability [5]. This gradual escalation allows your body to adapt to the medication's effects on gastric emptying and appetite regulation, significantly reducing the likelihood of persistent nausea or vomiting.

The KwikPen delivery device contains four pre-filled doses and requires no manual dose adjustment — you simply inject the pre-set amount once weekly on the same day each week. Injections are administered subcutaneously into the abdomen, thigh, or upper arm, with injection site rotation recommended to reduce localised reactions. Your Cured Pharmacy clinical team provides comprehensive injection technique guidance with every prescription.

Who Should Not Take Mounjaro: Contraindications and Precautions

Mounjaro is not suitable for everyone and carries specific contraindications that your UK prescriber must evaluate before issuing a prescription. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as tirzepatide caused thyroid C-cell tumours in rodent studies [5].

Additional contraindications include hypersensitivity to tirzepatide or any excipients, type 1 diabetes, diabetic ketoacidosis, severe gastrointestinal disease including inflammatory bowel disease, and pregnancy or breastfeeding [5]. Patients with a history of pancreatitis require careful evaluation, as GLP-1 receptor agonists have been associated with acute pancreatitis in rare cases.

Your Cured Pharmacy prescriber will also assess potential drug interactions, particularly with insulin or sulfonylureas which may require dose adjustment to prevent hypoglycaemia. Mounjaro delays gastric emptying, which can affect the absorption of oral medications — your clinical assessment will identify any medications requiring timing adjustments or closer monitoring.

Pregnancy and Reproductive Health Considerations

Women of childbearing potential should use effective contraception during Mounjaro treatment and for at least four weeks after the final dose, as tirzepatide may reduce the efficacy of oral contraceptives due to delayed gastric emptying [5]. If you are planning pregnancy, your prescriber will typically recommend discontinuing Mounjaro at least two months before attempting to conceive, given the long elimination half-life of approximately five days. Breastfeeding is not recommended whilst taking Mounjaro, as it is unknown whether tirzepatide is excreted in human milk.

Comparing Mounjaro to Other UK Weight Loss Treatments

The UK weight loss treatment landscape includes several evidence-based options, each with distinct mechanisms, efficacy profiles, and suitability for different patient populations. Understanding these differences helps you and your prescriber select the most appropriate treatment for your individual circumstances.

Injectable GLP-1 receptor agonists represent the most effective pharmacological option currently available. Wegovy (semaglutide) works through GLP-1 pathway activation alone and demonstrated average weight loss of 14.9% over 68 weeks in the STEP-1 trial [2]. Saxenda (liraglutide), a daily injection, showed average weight reduction of 8% over 56 weeks in clinical trials. Mounjaro's dual GIP/GLP-1 mechanism produces the highest average weight reduction in head-to-head comparisons, though individual response varies significantly.

Oral medications including Orlistat and Xenical work through a completely different mechanism — blocking pancreatic lipase enzymes to reduce dietary fat absorption by approximately 30% [6]. These treatments typically produce 5-10% weight loss when combined with reduced-calorie diets, with lower cost but requiring strict dietary fat restriction to avoid gastrointestinal side effects. Your Cured Pharmacy prescriber can discuss which option best aligns with your medical history, lifestyle, and weight loss goals during your free consultation.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. National Institute for Health and Care Excellence. (2024). Tirzepatide for managing overweight and obesity [TA1011]. NICE. https://www.nice.org.uk/guidance/ta1011
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of tirzepatide on glycaemic control and body weight in participants with type 2 diabetes: 104-week results from SURMOUNT-2. Diabetes, Obesity and Metabolism, 25(12), 3419–3429. https://doi.org/10.1111/dom.15239
5. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). eMC. https://www.medicines.org.uk/emc/product/14269/smpc
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and may not be suitable for everyone. Individual results vary and are not guaranteed.